Related Experiment Videos
Siramesine H Lundbeck
1moore11@globalnet.co.uk
Current Opinion in Investigational Drugs (London, England : 2000)
|January 31, 2002
Abstract:
Siramesine is a sigma2 opioid agonist under development by H Lundbeck as a potential treatment for anxiety 11678721. In March 1998, the compound was licensed to Forest Laboratories under a strategic alliance [282593]. In August 2000, siramesine entered phase II trials [378814]. Phase III trials are expected to take place in 2002 [387270]. A series of compounds have been synthesized by Lundbeck, the most potent of which may serve as a backup compound [179036].